Espace presse

Launch of the Medtech Generator & Accelerator program developed by Institut du Cerveau, Institut Imagine and Institut de la Vision

One quarter of severe forms of Covid-19 are explained by a genetic or immunological anomaly

A new treatment discovered at Institut Imagine and developed by QED Therapeutics enters clinical trial with a first child with achondroplasia in France

COVID-19: Institut Imagine and Cerba HealthCare are partnering to test for patients likely to develop severe symptoms

From rare to frequent: the importance of conducting research on genetic diseases

Autoimmune and inflammatory diseases associated with primary immune deficiencies: 11 major healthcare players in France commit to accelerating the development of precision medicine

Visit of the President of the Republic to Institut Imagine

Inauguration of Single-Cell@Imagine

Nature magazine's TOP 10 for 2020 : 15% of severe forms of Covid-19 are due to genetic and immunological abnormalities.

Type 1 Interferon Deficiency: A Blood based Signature for Detecting Patients at Risk of Severe Covid-19 for a therapeutic approach

Partnership research - Imagine launches a website dedicated to industrialists

World Sickle Cell Day: Hope for treatment with a new gene therapy approach

COVID-19: several Imagine teams mobilize

Teddy Riner supports Imagine in a national fundraising campaign

Let's speed up the diagnosis of genetic diseases